Washington [US], October 26 (ANI): Researczhers believed that the identification of a molecular connection between two proteins in brain cells that is linked in mice to the regulation of movement, anxiety, and memory may one day pave the way for the creation of novel treatments for schizophrenia.
The study team is the first to discover that the two proteins, which are among the dozens of proteins linked to an increased risk of developing schizophrenia, bind to one another normally in a number of brain regions, and that their interaction is essential for preserving normal movement, memory, and anxiety regulation in mice.
Researchers discovered that when the connection isn’t made correctly, the behaviour might suffer. In mice, for example, disruptions to the proteins’ capacity to interact led to increased hyperactivity, decreased risk avoidance, and memory impairments. Although hallucinations and delusions are the most common symptoms of schizophrenia, the illness can also cause mobility and memory issues.
“These two proteins are seemingly unrelated, and our study has provided a link between them that wasn’t recognized before,” said lead author Chen Gu, associate professor of biological chemistry and pharmacology in The Ohio State University College of Medicine.
“There are more than 100 genes that have been identified as risk genes for schizophrenia, but we still don’t know the real mechanisms behind those risks,” Gu said. “We’re hopeful that getting a better understanding of this mechanism could help in the long run to find a new treatment that could benefit patients with schizophrenia.”
The study was published recently in the journal Molecular Psychiatry.
Previous post-mortem studies have identified risk genes for schizophrenia based on signs of protein dysfunction detected in brain tissue. Among them are the proteins in this study: MAP6, which has a role in supporting a neuron’s cytoskeleton or, more specifically, microtubules, and Kv3.1, which helps control the maximal frequency of electrical signalling by neurons.
Gu’s lab has studied Kv3.1 for many years, often working with genetically altered mice lacking its gene. As the team began exploring a connection between Kv3.1 and MAP6, the first study author Di Ma, a graduate student in the lab, found that mice lacking the genes for both proteins experienced similar behaviour changes.
“That’s how we started looking at their relationship in more detail,” Gu said.
In this study, Ma and her lab mates took a more nuanced look at how the proteins’ connection relates to behaviour by disrupting their ability to bind to each other in specific brain regions in mice: the hippocampus, which governs learning and memory, and the nearby amygdala, where emotions are processed.
The researchers found that disruption to the proteins’ connection in the amygdala led to a reduction in risk avoidance – shown in mice as a lack of fear of heights. Blocking the proteins’ attachment in the hippocampus resulted in hyperactivity and lower recognition of a familiar object.
Though some behaviour changes in these experiments differed from the longer list of changes seen in mice completely lacking one or both genes, the finding provided important insights about where the proteins’ interactions, or lack thereof, have the strongest effect on behaviour.
“Different physiological functions we are engaged in daily are governed by different brain regions,” Gu said.
“That’s an advance provided by our study – because previously we only knew global knockout mice had these behavioural alterations, we didn’t really know what brain region was responsible for them.”
The next step in Gu’s lab will be exploring any links between social behaviour in mice and these proteins’ functions in the prefrontal cortex, a brain region important to decision-making and planning.
In a series of biochemistry and cell biology experiments, the researchers also determined how the proteins bind and how that connection affects their positioning inside neurons. Results showed MAP6 stabilizes the Kv3.1 channel in a specific type of interneurons, where it helps these cells keep brain signals at an even keel. A drop in the expression of MAP6, on the other hand, dramatically decreased the level of Kv3.1 in those interneurons.
The combined findings suggest that when the proteins don’t bind properly, there isn’t enough Kv3.1 available to maintain interneurons’ signal-control function, leading to an imbalance of neural inhibition and excitation in affected brain regions – and related negative behavioural symptoms. This type of interneuron, capable of generating nerve impulses in high frequencies, represents a key therapeutic target for schizophrenia.
“Our study further provides a link between the MAP6 dysfunction and the interneuron signal dysfunction, and we now know that there are two proteins that interact and that one could alter the other,” Gu said. “That opens up potential new directions for treatment strategies.” (ANI)
